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Barrett’s esophagus (BE) is the only known precursor to esophageal adenocarcinoma 
(EAC). Methods of identifying BE patients at high risk for progression to high-grade dysplasia 
(HGD) or EAC are needed to improve outcomes and identify who will benefit most from 
intensive surveillance or ablative therapy. Clinical predictors of BE progression to HGD or EAC 
are poorly understood, with multiple contradictory studies. We performed a retrospective study 
included 460 patients at Johns Hopkins Hospital who underwent at least 2 upper endoscopies 6 
months apart showing biopsy-documented BE between 1992 and 2013. Patients with EAC or 
HGD at the initial endoscopy were excluded. Demographic, clinicopathological, and endoscopic 
data were collected. Univariate and multivariate Cox proportional hazards analyses with time to 
progression to HGD and EAC were performed.  
Among 460 patients included in the study, 132 BE patients ultimately progressed to HGD 
and 62 developed EAC. Two hundreds and seventy two (272) BE patients did not progress to 
dysplasia or EAC. Significant EAC risk factors included age, abdominal obesity, caffeine intake, 
and the presence of HGD. Risk factors for HGD or EAC included age, caffeine intake, and low-
grade dysplasia while colonic adenomas trended towards significance. Notably, a history of 
statin or SSRI usage reduced the risk of EAC or HGD by 49% or 61%, respectively.  In sum, our 
study validated several known and identified several novel risk factors, including a history of 
colonic adenomas or caffeine usage. Low-grade dysplasia (LGD) was a risk factor for 
progression but various endoscopic characteristics were not, suggesting that screening strategies 
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The incidence of esophageal adenocarcinoma (EAC) has increased rapidly in the USA 
and other nations, but unfortunately, most cases are detected very late, with a fatality rate of 
90%.1 Barrett’s esophagus (BE), the only known precursor for EAC, can progress to low-grade 
dysplasia (LGD), high-grade dysplasia (HGD), or ultimately EAC. BE is defined as salmon-
colored mucosa extending ≥1 cm proximal to the gastroesophageal (GE) junction, with biopsy 
confirmation of replacement of normal squamous epithelium by metaplastic intestinal-type 
columnar epithelium.1 Endoscopic surveillance is currently accepted for all patients with BE, as 
BE surveillance carries an improved prognosis.2 Although BE patients have an eleven-fold 
higher risk of EAC than the general population, their annual risk of this malignancy is 0.11%.3 
These observations have generated controversy regarding cancer screening and surveillance 
practices. Since most BE patients will not develop EAC, and considering the risk and expense of 
endoscopic surveillance, understanding risk factors for BE progression is important to effectively 
focus resources on high-risk BE patients, allowing patient stratification and enabling tailored 
surveillance and therapy. 
Predictors of neoplastic progression in BE are incompletely understood. Epidemiologic 
risk factors considered include male gender, age, white race, obesity (especially central obesity), 
family history of BE or EAC, BE duration, endoscopic extent of BE, smoking, and GERD 
history.4 There is a strong correlation between frequent and prolonged acid exposure and BE 
development; moreover patients presenting with GERD at younger ages, or with longer GERD 
symptom duration, are at increased risk.5 Nevertheless, many EAC and HGD patients do not 
recall prior reflux symptoms. Proven endoscopic risk factors for BE progression include long BE  
segment length, hiatal hernia, mucosal abnormalities such as esophagitis, and the presence of BE  
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in a 12- to 6-o’clock esophageal hemisphere.1 Histologic factors, including intestinal metaplasia, 
low-grade dysplasia, and p53 overexpression are also suggested risk factors.1 
 The aims of our study are to comprehensively assess clinical, epidemiological, 
endoscopic, and histopathologic risk and protective factors for the progression of BE to either 
HGD or EAC. We reason that a clearer understanding of these factors would help optimize 
surveillance, since it would enable better resource allocation to surveil patients with positive, 



















METHOD AND MATERIALS  
This study was approved by the Institutional Review Board (IRB) at the Johns Hopkins 
University (JHU) School of Medicine. All patients undergoing ≥2 upper endoscopies (EGD) ≥6 
months apart, showing histologically confirmed BE from 1992-2013, were included. We 
excluded patients with <2 EGDs or <6 months between initial and most recent EGDs, or EAC or 
HGD at initial EGD.  Diagnosis was made by expert GI pathologists at JHU. The Center for 
Clinical Data Analysis (CCDA) at JHU assisted in identifying patients who underwent at least 2 
EGDs with 6 months apart. If Barrett’s esophagus was noted both endoscopically (at least 1 cm 
of salmon colored mucosa in the tubular esophagus with intestinal metaplasia on the pathology) 
the patients were included as potential patients for the study. Those developing HGD or EAC 
were termed progressors, while those remaining free of dysplasia, developing only LGD, or 
regressing to normal pathology without intervention were termed non-progressors.  
Baseline age, gender, race, and BMI were collected. Age was modeled as a continuous 
variable. Subjects fell into 3 categories of obesity: overweight (BMI 25-29.9), obese I (BMI 30-
34.9), or obese II (BMI > 34.9). Smoking was categorized as never, former, or current, with 
former subdivided into < 10, 10-30, or >30 pack-years. Alcohol use was categorized as former 
social, former heavy, current social, or current heavy. Illicit drug use was divided into drug type 
and categorized as either former or current. Caffeine intake was recorded as rare, weekly to 
daily, or multiple times daily.  Family history of other cancers, BE, esophageal cancer, or 
GERD/heartburn was recorded. Medications the patient took any time after initial BE diagnosis 
and before diagnosis of HGD or EAC were recorded. Other epidemiologic risk factors included 
history of esophagitis, gastric or duodenal ulcer, gastritis, esophageal stricture, esophageal web, 
and Schatzki’s ring. History of GERD, heartburn, dysphagia, regurgitation, and symptom 
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frequency were recorded, as were history of colonic adenoma, cholecystectomy, anti-reflux 
surgery, other cancers, hypertension, hyperlipidemia, diabetes, coronary artery disease, stroke, 
chronic kidney disease, and anemia. Endoscopic risk factors comprised presence and size of 
hiatal hernia, number and segment length of BE tongues, (long segment BE >3 cm, short 
segment BE <3 cm), BE circumferentially (>3 cm circumferential extent), presence of 
esophagitis, and presence of esophageal ulcer. Histopathologic risk factors comprised initial 
degree of dysplasia (low-grade or non-dysplastic).  
 
Statistical Analyses 
Demographic and clinicopathological variables were summarized with means and 
standard deviations for continuous variables or proportions for categorical variables. We first 
performed univariate logistic regression analysis with progression to EAC or the composite 
outcome of progression to EAC or HGD as the dependent variable and epidemiologic and 
clinical factors, medications and endoscopic features as independent variable. Any variable 
significantly associated with progression (p-value < 0.05) in the univariate analysis was 
highlighted as a potential risk or protective factor. Multivariate Cox models used least absolute 
shrinkage and selection operator (LASSO) penalized regression for model selection, which 
minimizes the usual sum of squared errors, with a bound on the sum of the absolute values of the 
coefficients.6 This method penalizes size of regression coefficients, whereby some predictors 
have coefficient estimates of exactly zero and can be considered "selected out" of the model. 
Variables with regression coefficients ≠0 were chosen for the multivariate Cox model. The tests 
for proportionality of hazards were done using methods as described by P. Grambsch and T. 
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Therneau where proportional hazards tests and diagnostics were based on weighted residuals.7 

























 We identified 460 patients with BE diagnosed during the study period (see Figure 1 for 
flow chart). Baseline characteristics are in Table 1 for progressors and non-progressors. We 
identified 272 as non-progressors and 188 as progressors. Among progressors, 19 patients were 
identified as low-grade dysplasia (LGD) BE and 169 patients were non-dysplastic BE (NDBE) at 
baseline. Average age for total cohort was 68.51 ± 13.03; 68% were males, 93% were non-
Hispanic Caucasians, and 51% had smoked tobacco. Common medications were proton pump 
inhibitors (94%), statins (37%), aspirin (30%), angiotensin receptor blockers (ARBs, 24%), 
angiotensin converting enzyme (ACE) inhibitors (18%), beta-blockers (11%) and selective 
serotonin re-uptake inhibitors (SSRIs, 11%).  
Of the 460 BE patients, 62 developed EAC and 132 developed HGD during the study 
period (Figure 1). The mean (SD) follow-up after BE diagnosis was 7.78 (5.40) years. HGD and 
EAC incidences were 49.19 and 16.48 per 1,000 person-years of follow-up, respectively; 10-year 
cumulative HGD and EAC incidences post-BE diagnosis were 0.40 and 0.17, respectively. 
Cumulative HGD and EAC incidence curves are in Figure 2.  
Results of univariate and multivariate analyses with progression to EAC as outcome are 
in Figure 3.  In univariate analysis, age, Hispanic race, abdominal obesity, history of diabetes 
mellitus, and oral non-metformin anti-diabetic medications were significant risk factors for 
progression, while SSRI usage trended strongly toward significance as protective (p=0.08). 
Metformin did not significantly increase or decrease progression risk. Weekly/daily caffeine 
(p=0.07), heavy smoking (p=0.07), family history of BE (p=0.09), and dysphagia (p=0.09) 
trended positively as risk factors.  Significant endoscopic risk factors were long-segment BE, 
presence of LGD, and development of HGD on subsequent endoscopies (patients with initial 
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HGD were excluded). As in univariate analysis, age, abdominal obesity, weekly caffeine intake, 
and oral anti-diabetic medications conferred significant risk, while family history of BE trended 
toward significance (p=0.10) in multivariate analysis. SSRIs were significantly protective in 
multivariate analysis (Figure 4). Endoscopic risk factors in multivariate analysis included only 
LGD and development of HGD on subsequent endoscopies. Notably, long-segment and 
circumferential BE were not risk factors in multivariable analysis after adjustment for 
confounding factors.   
A multivariate model was also performed with composite outcome of progression to 
either HGD or EAC (Figure 5). Significant risk factors in this model included age, weekly/daily 
and multiple daily caffeine usage; heavy smoking (>30 pack-years; p=0.09), colonic adenomas 
(p=0.08), and calcium channel blockers (p=0.06) trended positively as risk factors. Anemia, 
statins, and SSRIs (Figure 4c) were statistically significantly protective, while supplemental 
calcium/vitamin D trended towards significance as protective (p=0.08). Significant histologic 










 In this retrospective study of 460 patients with histologic BE, we applied multivariate 
regression model to identify clinical, epidemiologic, endoscopic, and histologic risk factors for 
progression BE to HGD or EAC. Our results validated known risk factors for progression, 
including age, abdominal obesity, and smoking, but also demonstrated, to our knowledge for the 
first time, that caffeine intake and colonic adenomas increase progression risk. While dysplasia 
increased progression risk, previously reported endoscopic factors - circumferential BE, long-
segment BE, and hiatal hernia - were not significant after multivariate adjustment for potential 
confounders. We also demonstrated protective effects for known chemoprotective medications, 
particularly statins, as well as several novel medications, notably SSRIs and supplemental 
calcium and vitamin D. 
Age constituted a strong risk factor for progression to either HGD or EAC in our study, 
consistent with prior studies and the increased incidence of EAC reported in the Surveillance, 
Epidemiology, and End Results (SEER) registry.8 Male gender is also a known risk factor for BE 
progression to EAC but was not significant in our study. However, SEER indicates that the 
largest gender difference occurs in patients younger than 65.8 Since our average age was 68, this 
may explain why our gender difference was not as large. Additionally regarding obesity, we 
found that central abdominal obesity was a significant risk factor for both HGD and EAC, but 
not increased BMI, suggesting that fat distribution primarily contributed to this risk. Tobacco 
usage is an established risk factor for BE progression, with conflicting data on caffeine usage. 
We found that heavy smoking (>30 pack-years) increased the composite risk of HGD or EAC by 
111%. Our study also found that caffeine was a significant risk factor for the composite outcome 
of HGD or EAC. This is consistent with the finding that caffeine induces gastric acid secretion, 
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relaxes the LES, and worsens GERD.9 However, multiple studies on caffeine have yielded mixed 
results, with one study finding an inverse association with coffee consumption and EAC rates, 
while another involving 400,000 participants did not.10, 11 Only 1 study addressed BE progression 
risk vs. coffee/tea consumption: it did not find any association.12 Our data showed that coffee and 
tea or caffeinated soft drink consumption, which had not been studied significantly, increased 
progression risk. 
Colonic adenomas trended toward significance for progression to either HGD or EAC in 
our study. Previous studies have shown that patients with colonic adenomas have a higher risk of 
BE, and patients with BE have a higher risk of colonic adenomas.13 However, to our knowledge, 
no studies looked at the relationship between colonic adenomas and BE progression risk. Several 
potential reasons may explain why colonic adenomas increase BE progression risk. First, they 
constitute a pre-malignant lesion with low-grade dysplasia and may represent a field defect 
evincing a genetic predisposition to the development of dysplasia. Indeed, inducible nitric oxide 
synthase and cyclooxygenase-2 are mediators of inflammation, regulators of cell growth, and 
elevated in colonic adenomas, colonic adenocarcinomas, BE, and EAC.14 Additionally, 17p and 
5q allelic losses are associated with progression of both colonic adenomas and BE.15 These 
common genetic alterations may explain why patients with colonic adenomas have a higher risk 
of BE progression. 
We found anemia to be potentially protective against progression to either HGD or EAC. 
One explanation is that anemic patients (who often undergo EGD for evaluation of anemia) 
represent a distinct population with a lower risk of BE progression vs. other BE patients, many of 
whom have longstanding GERD and additional risk factors and thus are screened for BE. Indeed, 
2 studies in patients undergoing colonoscopy for colon cancer screening showed high rates (11% 
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and 6.8%) of BE in asymptomatic patients.16 These studies also demonstrated that asymptomatic 
patients had a lower risk of long-segment BE, previously associated with progression. Thus, 
anemia per se may not protective, but patients found to have BE without GERD or other risk 
factors may not be at the same risk of progression to HGD/EAC.  
Previously identified endoscopic factors for BE progression include circumferential or 
long-segment BE17 and LGD3 or HGD18. In our study, long-segment BE and circumferential BE 
were significant only in univariate analysis but not after adjustment for other factors, divergent 
from prior studies. 17 Indeed, 69 different demographic, clinical, medication-related and 
endoscopic risk factors were measured in our multivariate analysis. Patients with long-segment 
BE or circumferential BE may also have concomitant risk factors increasing their progression 
risk. LGD was a significant risk factor to the composite outcome of HGD or EAC, and 
development of HGD during the study period was also a significant risk factor for progression to 
EAC, consistent with previous findings.19 These findings may also explain why current 
endoscopic surveillance has not reduced the incidence of EAC.20 Indeed, a recent meta-analysis 
demonstrated that 25% of patients with BE or BE with LGD developed an incident cancer within 
1 year of endoscopic screening, questioning the ability of endoscopy to appropriately risk-stratify 
patients.21 Another meta-analysis demonstrated that only 20% of EACs in BE patients were 
diagnosed via surveillance, whereas most EACs were prevalent, detected shortly after BE 
diagnosis and before potential intervention.22 This finding, combined with our study, suggests 
that the priority for screening is early dysplasia detection, rather than other endoscopic findings 
such as length or circumferential extent, since dysplasia confers the greatest progression risk. 
This argues that better methods/technologies facilitating early dysplasia detection are needed to 
improve detection of HGD early and intervention before EAC development. 
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Chemoprevention of cancer is a worthy goal, particularly in BE, given the increasing 
incidence of EAC and the widespread prevalence of GERD and BE. Multiple studies have shown 
that statins reduce neoplastic progression in BE, with proposed mechanisms including anti-
proliferative, anti-angiogenic, and pro-apoptotic effects.1 In our study, statins reduced the risk of 
progression to the composite outcome of HGD or EAC by 48% (OR = 0.52, 95% CI = 0.34 – 
0.79, p=0.002). NSAIDs and aspirin have also been shown in multiple studies to be protective, 
but were not in our study.23  
Two protective medications discovered by us were SSRIs and supplemental calcium or 
vitamin D. SSRIs have not been previously associated with a reduction in BE progression or 
EAC incidence. However, they exert anti-tumor effects relevant to colonic neoplasia. 
Specifically, SSRIs decrease cultured human colon cancer cell viability; suppress cell division in 
rat colonic tumors, and slow human colorectal tumor xenograft growth.24 Additionally, SSRIs 
reduce growth hormone and insulin-like growth factor (IGF) levels, and IGF participates in 
progression of BE to EAC, based on immunohistochemical analysis of human BE, LGD, HGD 
and EAC.25 Either of these mechanisms could potentially account for the protective effect of 
SSRIs. Vitamin D receptor expression is upregulated in BE, indicating a potential mechanism for 
the protective effect of vitamin D.26 
Our study possesses several strengths. We investigated a large cohort of patients 
previously diagnosed with BE over a 21-year period, some of whom developed EAC or HGD 
during follow-up. This study comprehensively examined clinical, epidemiological, endoscopic, 
and histopathological risk factors.  We documented not only basic clinical information, but also 
all medications taken, prior medical history, family history, endoscopy reports, and pathology 
findings. Many prior studies assessing risk factors were not so comprehensive. We also used 
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multivariate regression modeling to limit confounding factors, unlike most published studies. 
Additionally, we included large sub-cohorts of patients with HGD (132 patients) or EAC (62 
patients), allowing us to explore differences between progressors and non-progressors.  
One limitation of our study was its retrospective nature and its restriction to one academic 
center. Also, some bias may have occurred due to the tertiary nature of our center and the fact 
that many higher-risk patients were referred from other centers because of advanced endoscopic 
therapies available at our hospital. Thus, 29.4% of patients with BE in our study progressed to 
develop HGD or EAC, a rate higher than the general BE population. Therefore, one could argue 
this poses a threat to external validity. However, we should be aware that our study period 
includes the period of 1990’s where low-resolution endoscopes were used; thus, subtle 
abnormalities or early neoplastic lesions in the BE segment could have easily been missed. This 
could lead to inclusion of patients with prevalent advanced neoplasia at baseline that was missed 
on the initial endoscopy, explaining for the high progression rate among patients with NDBE.  
 In conclusion, this retrospective study validates several previously identified risk factors 
for BE progression, including age, heavy smoking, abdominal obesity, long-segment BE, and 
dysplasia, but it also identifies novel risk factors, including colonic adenomas and caffeine 
intake. We also identified statins, SSRIs, and supplemental calcium and vitamin D as potential 
protective agents, each with its own biologically plausible mechanisms. These medications merit 
further exploration in prospective studies, along with risk factors we identified, to improve 
identifying patients at greatest progression risk and thus likely to benefit from more frequent 





Table 1. Baseline characteristics of BE patients identified as progressors vs non-
progressors  
 





Age 67.01 +/- 12.99 74.34 +/- 11.73 
Gender (% Male) 174(64%) 146 (78%) 
Race 
Non-Hispanic Caucasian 247 (91%) 184 (98%) 
African American 16 (6%) 0 (0%) 
Hispanic 3 (1%) 4 (2%) 
Asian 6 (2%) 0 (0%) 
BMI 
< 25 62 (23%) 30 (16%) 
25-30 100 (37%) 67 (36%) 
> 30 110 (41%) 91 (49%) 
Alive 263 (97%) 178 (95%) 
Smoking History 
Never 138 (51%) 84 (45%) 
Former Smoker 100 (37%) 84 (45%) 
Current Smoker 34 (12%) 20 (10%) 
Alcohol Use 
Never 133 (49%) 72 (38%) 
Former Social Drinker 11 (4%) 9 (5%) 
Former Heavy Drinker 15 (5%) 12 (6%) 
Current Social Drinker 108 (40%) 93 (49%) 
Current Heavy Drinker 5 (2%) 2 (1%) 
Illicit Drug use 
Never 253 (93%) 180 (96%) 
Former User 8 (3%) 2 (1%) 
Current User 11 (4%) 6 (3%) 
Family History of Cancer 98 (36%) 96 (51%) 
Family History of BE 5 (2%) 5 (3%) 
Family History of Esophageal 
Cancer 
8 (3%) 8 (4%) 




NSAIDs 35 (13%) 28 (15%) 
PPIs 253 (93%) 184 (98%) 
H2 Blockers 27 (10%) 7 (4%) 
Statins 103 (38%) 66 (35%) 
Aspirin 82 (30%) 54 (29%) 
Metformin 22 (8%) 7 (4%) 
Oral Diabetic Medications 8 (3%) 2 (1%) 
Insulin 11 (4%) 13 (7%) 
ACEI 46 (17%) 38 (20%) 
ARB 68 (25%) 45 (24%) 
B-Blocker 27 (10%) 23 (12%) 
CCB 38 (14%) 34 (17%) 
Benzos 19 (7%) 9 (5%) 
SSRI 35 (13%) 9 (5%) 
ACEI/ARB 73 (27%) 58 (31%) 
Calcium/Vitamin D 56 (19%) 17 (9%) 
Diuretics 54 (20%) 36 (19%) 
Medical History 
Esophagitis 90 (33%) 60 (32%) 
Gastric Ulcer 5 (2%) 4 (2%) 
Duodenal Ulcer 5 (2%) 7 (4%) 
H. pylori 8 (3%) 2 (1%) 
Gastritis 40 (15%) 23 (12%) 
Esophageal stricture 11 (4%) 15 (8%) 
Esophageal Web 2 (1%) 0 (0%) 
Schatzki Ring 16 (6%) 4 (2%) 
GERD 266 (98%) 186 (99%) 
Colonic Adenomas 65 (24%) 70 (37%) 
Prior Cholecystectomy 33 (12%) 34 (18%) 
Prior Anti-Reflux Surgery 16 (6%) 7 (4%) 
Personal History of Cancer 35 (13%) 19 (15%) 
Hypertension 141 (52%) 113 (60%) 
Diabetes Mellitus 32 (12%) 24 (13%) 
Hyperlipidemia 87 (32%) 46 (34%) 
Coronary Artery Disease 35 (13%) 38 (20%) 
Prior stroke 5 (2%) 5 (3%) 
Chronic Kidney Disease 8 (3%) 5 (3%) 
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Anemia 29 (11%) 7 (4%) 
Solid Organ Transplant 3(1%) 2 (1%) 
Caffeine Use 112 (41%) 105 (56%) 
Heartburn 264 (97%) 180 (96%) 
Dysphagia 27 (10%) 38 (20%) 
Regurgitation 33 (12%) 36 (19%) 
Endoscopic Characteristics 
Hiatal Hernia 133 (49%) 100 (53%) 
Size of Hiatal Hernia 
Small 76 (28%) 43 (23%) 
Medium 22 (8%) 19 (10%) 
Large 35 (13%) 36 (19%) 
Circumferential BE 35 (13%) 107 (57%) 
Single BE Tongue 256 (94%) 173 (92%) 
Multiple BE Tongues 16 (6%) 15 (8%) 
Short Segment BE 215 (79%) 71 (38%) 
Long Segment BE 52 (19%) 116 (62%) 















































































Figure 4. Kaplan–Meier Survival Curves for progression to HGD (4A), EAC (4B), and 
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2012 The Lee B. Ashe Memorial Student Research Award, Howard University College 
of Medicine, Washington, D.C.   
 Awarded to the graduating senior who have demonstrated excellence in 
research and scholarship  
     
   2011 Alpha Omega Alpha (AOA) Honor Medical Society Inductee, Gamma Chapter , 
Howard University College of Medicine, Washington, D.C.   
 
   2008- 2012  Class rank: #5 
 Ranking out of a class of 120 matriculants at Howard University College of 
Medicine, Washington, D.C.       
 
   2011                            Pfizer Minority Medical Student Scholarship and Award, Washington, D.C.   
 Awarded per Dean’s nomination based on academic performance, 
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   2011                            Dr. JC Carr Foundation Merit Achievement Award and Scholarship      
 Awarded to the student top 25% of the respective class at Howard 
University College of Medicine, Washington, D.C.  
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   2010                            Dr. Linda Fardan Scholarship, Howard University College of Medicine 
 Awarded to student based on personal needs and academic 
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Medicine, Washington, D.C.  
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   2009           Howard University Robert Lee Academic Scholarship, Washington, D.C. 
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   2006    Phi Beta Kappa, Sigma Chapter, UC San Diego, La Jolla, CA    
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